Details of the Drug Combination

General Information of Drug Combination (ID: DC080Q4)

Drug Combination Name

Tranexamic Acid Hyaluronic acid

Indication

Disease Entry	Status	REF
Injection Site Bruising	Phase 4	[1]

Component Drugs

Tranexamic Acid DMFI8A7

Hyaluronic acid DMABXOZ

Small molecular drug

N.A.

2D MOL

3D MOL

3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Tranexamic Acid

Disease Entry	ICD 11	Status	REF
Excessive bleeding	GA30.02	Approved	[2]
Menorrhagia	GA20.50	Approved	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Endometriosis	GA10	Investigative	[3]

Tranexamic Acid Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Inhibitor	[5]
------------------------------------------------------------------------------------

Hyaluronic acid Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Hyaluronoglucosaminidase (nagH)	DEV7UZD	NAGH_CLOPE	Metabolism	[6]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04373603) Use of Tranexamic Acid in Facial Fillers
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6573).
3	Tranexamic acid FDA Label
4	Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients (TCInpatient)
5	Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
6	An extracellular enzyme with hyaluronidase and chondroitinase activities from some oral anaerobic spirochaetes. Microbiology. 1996 Sep;142 ( Pt 9):2567-76.